Lexicon Pharmaceuticals’ (NASDAQ:LXRX) LX9211 received FDA fast track designation for the treatment of diabetic peripheral neuropathic pain.
The company is currently enrolling patients with diabetic peripheral neuropathic pain in a Phase 2 proof-of-concept study of LX9211, a small molecule inhibitor of adapter-associated kinase 1.
“The FDA’s fast track designation of LX9211 reflects the serious unmet medical need of people suffering from diabetic peripheral neuropathic pain,” Praveen Tyle, Ph.D., Lexicon’s executive vice president of R&D, said in a statement.
“We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible,” he added.
